Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-09)
Approved for use through 03/31/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10551317
Filing Date	2006-08-21
First Named Inventor	Christof Westenfelder
Art Unit	1633
Examiner Name	WEHBE, Anne Marie Sabrina
Attorney Docket Number	38447-201N01US

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							☐

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10551317
	Filing Date	2006-08-21
	First Named Inventor	Christof Westenfelder
	Art Unit	1633
	Examiner Name	WEHBE, Anne Marie Sabrina
	Attorney Docket Number	38447-201N01US

	1	ABKOWITZ, J.L. et al., "Multilineage, non-species specific hematopoietic growth factor(s) elaborated by a feline fibroblast cell line: enhancement by virus infection", J. Cell Physiol. (1986), 127(1):189-96.	☐
	2	AGBULUT O. et al., "Temporal patterns of bone marrow cell differentiation following transplantation in doxorubicin-induced cardiomyopathy", Cardiovasc. Res. (2003), 1, 58(2):451-9.	☐
	3	ANGELOPOULOU M. et al., "Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice", Exp. Hematol. (2003), 31(5):413-20.	☐
	4	ANKER P.S. et al., "Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34+ cells in NOD/SCID mice", Exp. Hematol. (2003), 31(10):881-9.	☐
	5	BALLAS C.B. et al., "Adult bone marrow stem cells for cell and gene therapies: implications for greater use", J. Cell Biochem Suppl. (2002), 38:20-8.	☐
	6	BARRY F.P., "Biology and clinical applications of mesenchymal stem cells", Birth Defects Res. Part C Embryo Today, (2003), 69(3):250-6.	☐
	7	BENSIDHOUM M. et al., "Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse. Their role in supporting human CD34 cell engraftment", Blood, (2004), 103(9):3313-3319.	☐
	8	BONNET D., "Biology of human bone marrow stem cells", Clin. Exp. Med. (2003), 3(3):140-9.	☐
	9	BRON D., "Hematopoietic stem cells: source, indications and perspectives [Article in French]", Bull Mem. Acad. R. Med. Belg. (2002), 157(1-2):135-45.	☐
	10	BUEREN J.A. et al., "Genetic modification of hematopoietic stem cells: recent advances in the gene therapy of inherited diseases", Arch. Med. Res. (2003), 34(6):589-99.	☐
	11	BURT R.K., "Hematopoietic stem cell therapy for type 1 diabetes: induction of tolerance and islet cell neogenesis", Autoimmun. Rev. (2002): 1(3):133-8.	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (10/13/2010)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10551317
	Filing Date	2006-08-21
	First Named Inventor	Christof Westenfelder
	Art Unit	1633
	Examiner Name	WEHBE, Anne Marie Sabrina
	Attorney Docket Number	38447-201N01US

	12	CAPLAN A.I. et. al., "Cell-based tissue engineering therapies: the influence of whole body physiology", Adv. Drug Deliv. Rev. (1998), 33(1-2):3-14.	☐
	13	CASHMAN J.D. et al., "Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-beta", Blood, (1990), 75(1):96-101.	☐
	14	CHENG L et. al., "Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34(+) hematopoietic progenitor cells", J. Cell Physiol. (2000), 184(1):58-69.	☐
	15	DEANS R.J. et. al., "Mesenchymal stem cells: biology and potential clinical uses", Exp. Hematol. (2000), 28(8):875-84.	☐
	16	DELWICHE F. et. al., "Platelet-derived growth factor enhances in vitro erythropoiesis via stimulation of mesenchymal cells", J. Clin. Invest. (1985), 76(1):137-42.	☐
	17	DEVINE S.M. et. al., "Role of mesenchymal stem cells in hematopoietic stem cell transplantation", Curr. Opin. Hematol. (2000), 7(6):358-63.	☐
	18	DEVINE S.M. et. al., "Mesenchymal stem cells: stealth and suppression", Cancer J. (2001), 7 Suppl. 2:S76-82.	☐
	19	DOOLEY D.C. et. al., "Basic fibroblast growth factor and epidermal growth factor downmodulate the growth of hematopoietic cells in long-term stromal cultures;", J. Cell Physiol. (1995), 165(2):386-97.	☐
	20	EAVES C.J. et. al., "Regulation of hemopoietic progenitor cell proliferation", Behring Inst Mitt. (1988), 83:85-92.	☐
	21	FIBBE W.E. et al., "Mesenchymal stem cells and hematopoietic stem cell transplantation", Ann. N.Y. Acad. Sci. (2003), 996:235-44.	☐
	22	FORBES S.J. et. al., "Adult stem cell plasticity: new pathways of tissue regeneration become visible", Clin. Sci. (2002), 103(4):355-69.	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (10/13/2010)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10551317
	Filing Date	2006-08-21
	First Named Inventor	Christof Westenfelder
	Art Unit	1633
	Examiner Name	WEHBE, Anne Marie Sabrina
	Attorney Docket Number	38447-201N01US

	23	FORBES S.J. et. al., "Hepatic and renal differentiation from blood-borne stem cells", Gene Ther. (2002), 9(10):625-30.	☐
	24	HAYAKAWA J. et. al., "Generation of a chimeric mouse reconstituted with green fluorescent protein-positive bone marrow cells: a useful model for studying the behavior of bone marrow cells in regeneration in vivo", Int. J. Hematol. (2003), 77(5);456-62.	☐
	25	HEIKE et al., "Stem cell plasticity in the hematopoietic system", Int. J. Hematol. (2004), 79(1):7-14.	☐
	26	HIRSCHI K.K. et. al., "Hematopoietic, vascular and ca'rdiac fates of bone marrow-derived stem cells", Gene Ther. (2002), 9(10):648-52.	☐
	27	HORWITZ E.M., "Bone marrow transplantation: it's not just about blood anymore!", Pediatr. Transplant. (2003), 7 Suppl. 3:56-8.	☐
	28	HORWITZ E.M., "Stem cell plasticity: the growing potential of cellular therapy.", Arch. Med. Res. (2003), 34(6):600-6.	☐
	29	HUGHES S., "Cardiac stem cells", J. Pathol. (2002), 197(4):468-78.	☐
	30	IMAI E et al., "Can bone marrow differentiate into renal cells?", Pediatr Nephrol (2002), 17(10):790-4.	☐
	31	IMASAWA et al., "The potential of bone marrow-derived cells to differentiate to glomerular mesangial cells", J. Am. Soc. Nephrol (2001), 12(7):1401-9.	☐
	32	ITO T. et. al., "Application of bone marrow-derived stem cells in experimental nephrology", Exp. Nephrol. (2001), 9 (6):444-50.	☐
	33	JUSTESEN J. et. al., "Mesenchymal stem cells. Potential use in cell and gene therapy of bone loss caused by aging and osteoporosis", Ugeskr Laeger (2001), 163(40):5491-5.	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (10/13/2010)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10551317
	Filing Date	2006-08-21
	First Named Inventor	Christof Westenfelder
	Art Unit	1633
	Examiner Name	WEHBE, Anne Marie Sabrina
	Attorney Docket Number	38447-201N01US

	34	KADEREIT S. et. al., "Expansion of LTC-ICs and maintenance of p21 and BCL-2 expression in cord blood CD34(+)/ CD38(-) early progenitors cultured over human MSCs as a feeder layer", Stem Cells (2002), 20(6):573-82.	☐
	35	KATO Y. et. al., "Recipient non-hematopoietic bone marrow cells in then intestinal graft after fetal small intestinal transplantation", Pediatr. Surg. Int. (2004), 20(1):1-4.	☐
	36	KIM, J.H. et. al., "Co-transplantation of ex-vivo culture-expanded human mesenchymal stem cells and allogeneic hematopoietic stem cell transplantation - report of 12 cases", Blood (2002), 100(11): Abstract 4234.	☐
	37	KOC O.N. et. al., "Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy", J. Clin. Oncol. (2000), 18(2):307-16.	☐
	38	KRAUSE D.S. "Plasticity of marrow-derived stem cells", Gene Ther. (2002), 9(11):754-8.	☐
	39	KUCIA M. et. al., "Tissue-specific muscle, neural and liver stemlprogenitor cells reside in the bone marrow, respond to an SDF-1 gradient and are mobilized into peripheral blood during stress and tissue injury", Blood Cells Mol. Dis. (2004), 32(1):52-7.	☐
	40	LE BLANC K., "Mesenchymal stem cells. Basic science and future clinical use [Article in Swedish]", Lakartidningen, (2002), 99(12):1318-21.	☐
	41	LEE K. et. al., "Human mesenchymal stem cells maintain transgene expression during expansion and Differentiation", Mol. Ther. (2001), 3(6):857-66.	☐
	42	MACKENZIE T.C. et. al., "Human mesenchymal stem cells persist, demonstrate site-specific multipotential differentiation, and are present in sites of wound healing and tissue regeneration after transplantation into fetal sheep", Blood Cells Mol. Dis. (2001), 27(3):601-4.	☐
	43	MAJUMDAR M.K. et. al., "Characterization and functionality of cell surface molecules on human mesenchymal stem cells", J. Biomed. Sci. (2003), 10(2):228-41.	☐
	44	MAITRA B. et. al., "Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation", Bone Marrow Transplant. (2004), 33(6):597-604.	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (10/13/2010)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10551317
	Filing Date	2006-08-21
	First Named Inventor	Christof Westenfelder
	Art Unit	1633
	Examiner Name	WEHBE, Anne Marie Sabrina
	Attorney Docket Number	38447-201N01US

	45	MBALAVIELE G. et. al., "Human mesenchymal stem cells promote human osteoclast differentiation from CD34+ bone marrow hematopoietic progenitors", Endocrinology (1999), 140(8):3736-43.	☐
	46	NOORT W.A. et. al., "Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived;" CD34(+) cells in NOD/SCID mice", Exp. Hematol. (2002), 30(8):870-8.	☐
	47	ORLIC D., "Adult bone marrow stem cells regenerate myocardium in ischemic heart disease", Ann. N.Y. Acad. Sci. (2003), 996:152-7.	☐
	48	POULSOM R., "Does bone marrow contain renal precursor cells?", Exp. Nephrol. (2003), 93(2):e53.	☐
	49	RATAJCZAK M.Z., "Stem cell plasticity revisited: CXCR4-positive cells expressing mRNA for early muscle, liver and neural cells 'hide out' in the bone marrow", Leukemia (2004), 18(1):29-40.	☐
	50	RINGE J. et. al., "Stem cells for regenerative medicine: advances in the engineering of tissues and organs", Naturwissenschaften (2002), 89(8):338-51.	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (10/13/2010)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10551317
	Filing Date	2006-08-21
	First Named Inventor	Christof Westenfelder
	Art Unit	1633
	Examiner Name	WEHBE, Anne Marie Sabrina
	Attorney Docket Number	38447-201N01US

	1	TOCCI A. et. al., "Mesenchymal stem cell: use and perspectives", Hematol. J. (2003), 4(2):92-6.	☐
	2	TUAN R.S. et. al., "Adult mesenchymal stem cells and cell-based tissue engineering", Arthritis Res. Ther. (2003), 5 (1):32-45.	☐
	3	VAN DAMME A. et. al., "Bone marrow stromal cells as targets for gene therapy", Curr. Gene Ther. (2002), 2 (2):195-209.	☐
	4	YOKOO T. et. al., "Stem cell gene therapy for chronic renal failure", Curr. Gene Ther. (2003), 3(5):387-94.	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Anne Marie Wehbe/ (10/13/2010)	Date Considered	10/13/10

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (11/18/2010)